Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Rheincell develops and manufactures GMP-grade human induced pluripotent stem cells (iPSCs) for the next generation of cell therapies. Our production pipeline focuses on high immune compatibility and low rejection potential, with a spotlight on solutions for off-the-shelf, allogenic therapeutics. To that end, we have constructed a unique business framework: exclusive access to clinically approved and consented cord blood cells,...
Rheincell develops and manufactures GMP-grade human induced pluripotent stem cells (iPSCs) for the next generation of cell therapies. Our production pipeline focuses on high immune compatibility and low rejection potential, with a spotlight on solutions for off-the-shelf, allogenic therapeutics. To that end, we have constructed a unique business framework: exclusive access to clinically approved and consented cord blood cells, proprietary cell reprogramming protocols, state-of-the-art clean room and cell culture facilities, GMP-compliant manufacturing processes, and a first-class community of iPSC workflow experts.

List your booth number for exhibitions, ask us